×
{"type":"img","src":"//cdn.quv.kr/vzwi0cy6x/up/64390eaccc743_1920.png","height":40}
  • ABOUT US
  • R&D
  • IR
  • PR
  • CONTACT
  • {"google":["Noto Sans"],"custom":["Noto Sans KR"]}
    ×
     
     
    섹션 설정
    {"type":"img","src":"//cdn.quv.kr/vzwi0cy6x/up/5e1adcec2c4de_1920.png","height":"21"}
  • 기업소개
  • 연구개발
  • 투자정보
  • 홍보
  • CONTACT
  • 홍보

    A&T Pharma will become Korea's biopharmaceutical in the future through continuous research and development.

    We will do our best to contribute to export.

    PRESS

    News

    NOTITLEDATE
    4
    [YONHAP NEWS]Gangwon-do holds an investment agreement ceremony worth 113.7 billion won
    2023-12-20
    3
    [강원도민일보]Chuncheon City-A&T Pharma Sign Investment Agreement worth 19.4 Billion
    2023-12-20
    2
    [BIOTIMES] A&T Pharma proceeds smoothly with preclinical trials for commercial production of botulin
    2023-06-08
    1
    [senTV] A&T Pharma has launched a botulinum toxin business
    2023-04-17

    글쓰기

    {"google":["Noto Sans"],"custom":["Noto Sans KR"]}{"google":["Noto Sans"],"custom":["Noto Sans KR"]}
    {"google":[],"custom":["Noto Sans KR"]}